Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER)

被引：0
|
作者：
Fernandez, M.
Calvo, I.
Martinez, N.
Herrero, M.
Quijano, Y.
Duran, H.
Garcia-Aranda, M.
Suarez, A.
-Rios, F. Lopez
Perez, D.
Perea, S.
Hidalgo, M.
Garcia-Estevez, L.
机构：
[1] Ctr Integral Oncol Clara Campal, Madrid, Spain
[2] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[3] Hosp Costa del Sol, Marbella, Spain
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P1-14-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-14-10
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Effect of a combination of pertuzumab, trastuzumab, and weekly paclitaxel on pCR rates and side-effect profile as a neoadjuvant treatment regimen for HER2-positive breast cancer.
    Gupta, Niraj K.
    Giblin, Erica
    Leagre, Christopher A.
    Govert, Kristen
    Givens, Stanley
    Chichester, Tiffany
    Locker, Matthew
    Bhayani, Parin
    Burnett, Riesa
    Spivey, Tara
    Cohen, Stephanie
    Paul, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Docetaxel, carboplatin and weekly trastuzumab are active as neoadjuvant therapy in operable HER2-positive breast cancer
    Kolberg, H. -C.
    Akpolat-Basci, L.
    Otterbach, F.
    Drumm, A.
    Tirier, C.
    BREAST, 2011, 20 : S74 - S74
  • [43] COMBINATION OF TRASTUZUMAB, OXALIPLATIN AND DOCETAXEL AS FIRST LINE TREATMENT IN HER2-POSITIVE ADVANCED BREAST CANCER PATIENTS: PRELIMINARY RESULTS OF A PHASE II TRIAL (HOT TRIAL)
    Amoroso, Domenico
    Donati, Sara
    Rondini, Marianna
    Valsuani, Chiara
    Siclari, Olimpia
    Puccetti, Cheti
    Tartarelli, Gianna
    Puccinelli, Paolo
    Giannessi, Piergiorgio
    Falcone, Alfredo
    Camerini, Andrea
    ANNALS OF ONCOLOGY, 2009, 20
  • [44] Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Kikuchi, M.
    Sato, A.
    Ishikawa, Y.
    Odawara, H.
    Iino, Y.
    Takeyoshi, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Paclitaxel, Carboplatin, and Trastuzumab in a Neoadjuvant Regimen for HER2-Positive Breast Cancer: The TRAIN Study.
    Sonke, G. S.
    Mandjes, I. A.
    Holtkamp, M.
    Schot, M.
    Oosterkamp, H. M.
    Wesseling, J.
    Vrancken, Peeters M-J T.
    Rodenhuis, S.
    Linn, S. C.
    CANCER RESEARCH, 2011, 71
  • [46] NSABP FB-7 Trial: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer
    Lu, J.
    Jacobs, S. A.
    Buyse, M. E.
    Paik, S.
    Wolmark, N.
    CANCER RESEARCH, 2012, 72
  • [47] Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
    Tanioka, M.
    Fan, C.
    Carey, L. A.
    Hyslop, T.
    Pitcher, B. N.
    Parker, J. A.
    Hoadley, K. A.
    Henry, N. L.
    Tolaney, S.
    Dang, C.
    Krop, I. E.
    Harris, L.
    Berry, D. A.
    Mardis, E.
    Perou, C. M.
    Winer, E. P.
    Hudis, C. A.
    CANCER RESEARCH, 2017, 77
  • [48] Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
    Liang Huang
    Da Pang
    Hongjian Yang
    Wei Li
    Shusen Wang
    Shude Cui
    Ning Liao
    Yongsheng Wang
    Chuan Wang
    Yuan-Ching Chang
    Hwei-Chung Wang
    Seok Yun Kang
    Jae Hong Seo
    Kunwei Shen
    Suphawat Laohawiriyakamol
    Zefei Jiang
    Haiyan Wang
    François Lamour
    Grace Song
    Michelle Curran
    Chunzhe Duan
    Sanne Lysbet de Haas
    Eleonora Restuccia
    Zhimin Shao
    Nature Communications, 15
  • [49] Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer
    Overmoyer, Beth
    Regan, Meredith
    Hu, Jiani
    Nakhlis, Faina
    Dominici, Laura
    Lin, Nancy U.
    Freedman, Rachel
    Morganstern, Daniel E.
    Partridge, Ann H.
    Schlosnagle, Emily J.
    Hirshfield-Bartek, Judi
    Bellon, Jennifer
    Morikawa, Aki
    Harrison, Beth T.
    Winer, Eric
    CANCER RESEARCH, 2018, 78 (04)
  • [50] Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer
    Infante, Jeffrey R.
    Yardley, Denise A.
    Burris, Howard A., III
    Greco, F. Anthony
    Farley, Cindy P.
    Webb, Charles
    Spigel, David R.
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (01) : 23 - 28
12345